Indeed, therapeutic strategies targeting IgE, such as omalizumab, reduce airway and tissue remodeling in allergic inflammatory conditions including as asthma and atopic dermatitis (Oettgen, 2016; Strunk and Bloomberg, 2006). The gene discussed is IGHE; the disease is asthma.